medigraphic.com
Colegio de Medicos y Cirujanos República de Costa Rica

2009, Número 589

<< Anterior Siguiente >>

Rev Med Cos Cen 2009; 66 (589)


P53 y alfa-feto-proteina

Varela RL

Idioma: Español
Referencias bibliográficas: 33
Paginas: 299-304
Archivo PDF: 402.81 Kb.


RESUMEN

Medición de la actividad de los marcadores inmunohistoquímicos de p53 y alfa-fetoproteína en biopsias hepáticas con los diagnósticos de hepatitis crónica y cirrosis hepática por el virus de la hepatitis C (6) y el hepatocarcinoma en general.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Allende Daniela S and Yerian Lisa. Inmunohistochemical Markers in the Diagnosis of Hepatocellular Carcinoma. Pathology Case Reviews 2009; 14: 40-46.

  2. ARMSTRONG GL, ALTER MJ, McQUILLAN GM, MARGOLIS HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology, 2000; 31: 777-782.

  3. BLACKBURN, EH. Switching and signaling at the telomere. Cell, 2001; 106: 661-673.

  4. Bosch Barrera J, Lopez – Picazo Gonzalez J.M., Garcia – Foncillas Lopéz J, Prósper Cardoso F. Células Madre y Cáncer: dilucidando el origen de la célula madre tumoral. Rev Med Univ Navarra/Vol 51, N°2, 2007, 14 – 17.

  5. CAPOCACCIA RICCARDO, Sant Milena, Berrio Franco, Simonetti Arianna, Santi Valentina, Trevisani Franco and the Eurocare Working Group. Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th century. AM.J. Gastroenterol, 2007; 102: 1661-1670.

  6. CHOO Q-L, Kuo G, WEINER AM, JONES DB. Isolation of Ac DNA clone derived from A blood-borne non-A, non-B viral hepatitis genome. Science, 1989; 244: 359-362.

  7. DAVILA JA, MORGAN RO, SHAIB Y, McGLYNN KA, EL-SERAG HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology, 2004; 127: 1372-1380.

  8. EL-SERAG HB, DAVILA JA, PETERSEN NJ, MCGLYNN KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med, 2003; 139: 817-823.

  9. EL-SERAG HB, MASON AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med, 1999; 340:745-750.

  10. EL-SERAG HB, MASON AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med, 2000; 160: 3227-3230.

  11. EL-SERAG HB, RUDOLPH KL. Hepato-cellular carcinoma: Epidemiology and Molecular Carcinogenesis. Gastroenterology, 2007; 132: 2557-2576.

  12. EL-SERAG HB. Hepatocellular carci-noma: recent trends in the United States. Gastroenterology, 2004; 127 (5 suppl 1): S27-S34.

  13. FAUCI, Anthony S; BRAUNWALD, Eugene. Harrison. Principios de Medicina Interna. McGraw Hill, 17ª Edición. 2008.

  14. FIBBE WILLEM, E. Telomerase mutatios in aplastic anemia. Editorials. N Engl J Med, 2005; 352: 1481-1482

  15. FRÖHLING, Stefan; DÖHNER, Hartmut. Chromosomal abnormalities in cancer. New England. J Med, 2008 August 14; 359: 722-734.

  16. HAYFLICK, L. The limited in vitro lifetime of human diploid cell strains. Exp. Cell Res, 1965; 37: 614-636.

  17. LANED P. p53: guardian of the genome. Nature, 1992; 358: 1516.

  18. LLOVET Presentación oral, 2007. Annual Meeting, 4 junio 2007. Chicago, IL, USA.

  19. MITCHELL, Peter. Acoplamiento de la fosforilación a la transferencia de electrones e hidrógeno mediante un mecanismo de tipo quimiosmótico. Nature, 1961; Volume 191: 144-148.

  20. NEAL KEITH, R. On Behalf of the Trent Hepatitis C Study Group. GUT 2007; 56: 1098-1104.

  21. PARKIN DM, BRAY F. Estimating the world cancer burden: Globocan 2000. Int I Cancer 2001; 94:153-156.

  22. PAZ BOUZA, José Ignacio. Aspectos histopatológicos de diferentes órganos del ratón inoculados con virus herpes simples de tipo I y II. Tesis Doctoral. Facultad de Medicina. Universidad de Salamanca. España. 1978.

  23. POTENZA, Leonardo; LUPPI, Mario; BAROZZI, Patrizia. HHV- GA syncytial giantcell hepatitis. New England. J Med, Number 6. 2008 August 7; 359: 593-602.

  24. ROSENTHAL, Nadia. Prometheus’s Vulture and stem-cell promise. Number 3. New England. Journal of Medicine, 2003 July 17; 349: 267-274.

  25. RUDOLPH KL, CHANG S, MILLARD M, SCHREIBER-AGUS N, DEPINHO RA. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science, 2000; 287: 1253-1258.

  26. SÁNCHEZ POSADA, Raúl. Características biológicas de la célula en el cáncer de colon con metástasis ganglionares. Tesis Doctoral. Salamanca, 2007.

  27. SUN WEI, XING BAOCAL. Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electroforesis. Molecular and Cellular proteomics, 2007; 6: 1798-1808.

  28. TANG. Weiliang; LAZARO, Catherine A. Responses of non transformed human hepatocytes to conditional expression of full-iength hepatitis C virus open reading frame. Am J Pathol, 2007; 171: 1831-1846.

  29. WONG JB, McHUTCHISON JG, POYNARD T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health, 2000; 90: 1562-1569.

  30. YOSHIZAWA H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology, 2002; 62 (suppl 1): 8-17.

  31. YU MW, CHEN CJ. Elevated serum testosterone levels and risk of hepatocellular carcinoma. Cancer Res, 1993; 53: 790-794.

  32. YU MW,YANG YC, YANG SY. Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men. J Natl Cancer Inst, 2001; 93: 1644-1651.

  33. ZEN YOH, FUJII TAKAHIKO. Histological and culture studies respect to ABC62 expression support the existence of a cancer cell hierarchy in human hepatocellular carcinoma. AJP, 2007; 170: 1750-1762




2020     |     www.medigraphic.com